Ethical Approval of XNW3009 for PhII Trial

XNW3009 of Evopoint is one of the new generation of hURAT1 selective inhibitors.
On January 22, 2021, XNW3009 received ethical approval for phase II clinical trial, and will soon start domestic phase II clinical trial.